IBD Management Strategies to Improve Remission Rates and Prevent Disease Relapse Webcast

Release Date: December 13, 2016
Expiration Date: December 13, 2017
Expected time to completion: 1.5 hours 

Moderator

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania

Faculty

Marla C. Dubinsky, MD
Chief, Pediatric Gastroenterology, Hepatology, & Nutrition
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Department of Pediatrics
Icahn School of Medicine at Mount Sinai
New York, New York

William J. Sandborn, MD
Professor of Medicine
Department of Medicine
Chief, Division of Gastroenterology
University of California, San Diego
La Jolla, California

Program Overview

Inflammatory bowel disease (IBD) is a group of chronic idiopathic inflammatory disorders of the gastrointestinal tract, which includes ulcerative colitis and Crohn’s disease, and is characterized by recurrent exacerbations and remissions. Since there is currently no medical or surgical cure, patients affected by IBD require lifelong therapeutic approaches in order to reduce symptoms, improve their quality of life, and avoid hospitalizations and surgery. Corticosteroids have historically been the mainstay for the initial treatment of mild-to-moderate disease with anti-inflammatories used as maintenance therapy. However, the management of patients with IBD has undergone a shift with the development of biologic therapies. In individuals with moderate-to-severe IBD, these therapies have been found to reduce symptoms, heal mucosal ulcers, decrease hospitalizations and surgeries, and spare the use of corticosteroids, which have been associated with dependency and frequent, sometimes severe, adverse events.

Clinicians are confronted with the challenging task of evaluating individual patient characteristics in order to stratify risk, initiate individualized therapy, monitor therapeutic response, and tailor therapeutic regimens in the event of disease recurrence. This interactive panel discussion utilizes a case-based approach to review the most recent evidence regarding the predictive value of biomarkers in IBD, monitoring strategies, and individualization of patient management plans.

Target Audience

This educational initiative has been designed for gastroenterologists involved in the management of patients with IBD.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Incorporate the use of clinical tools that help identify and accurately diagnose patients with mild-to-moderate IBD
  • Apply individualized treatment strategies for managing patients with mild-to-moderate IBD
  • Describe strategies for actively monitoring treatment response and risk for symptom recurrence

Directions to Learner

There are no fees for participating and receiving CME credit for this enduring activity. During the period of December 13, 2016 through December 13, 2017, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

Media

Internet

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest (COI)

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Gary R. Lichtenstein, MD
Consulting fees: Abbott Corporation/Abbvie, Actavis, Alaven, Celgene, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, Takeda, UCB
Contracted research: Celgene, Ferring, Janssen Biotech, Prometheus Laboratories, Inc., Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, UCB
Royalty: SLACK, Inc.
Other: Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications), Ironwood, Luitpold/American Regent, McMahon Publishing, Merck, Springer Science and Business Media, Up-To-Date; Funding to University of PA (IBD Fellow Education)

Marla C. Dubinsky, MD
Consulting fees: AbbVie, Boehringer Ingelheim, Celgene, Genentech, Janssen, Pfizer, Salix, Takeda, and UCB

William J. Sandborn, MD
Consulting fees: Abbvie, Amgen, Boehringer Ingelheim, Celgene/Receptos, Genentech, Gilead Sciences, Janssen, Lilly, Pfizer, Prometheus Laboratories, Shire, Takeda, UCB
Contracted research: Abbvie, Amgen, Boehringer Ingelheim, Genentech, Gilead Sciences, Janssen, Pfizer, Prometheus Laboratories, Receptos, Takeda
Speakers’ bureaus: Janssen, Takeda

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity provided by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

Minimum System Requirements

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2 Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Continue to Pretest

pre

integrity
 Provided by Integrity Continuing Education, Inc.

Supported by an educational grant from Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC.